IHEM   20887
INSTITUTO DE HISTOLOGIA Y EMBRIOLOGIA DE MENDOZA DR. MARIO H. BURGOS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
CDC42 as an epigenetic regulator of ID4 in breast cancer
Autor/es:
ROQUÉ MORENO, MARÍA; NASIF, DANIELA LUCÍA; BRANHAM, MARÍA T.; LAURITO, SERGIO
Lugar:
Aguas de Lindoia, Sao Paulo
Reunión:
Simposio; 48th Annual Meeting of the Brazilian Society for Biochemistry and Molecular Biology (SBBq); 2019
Institución organizadora:
Brazilian Society for Biochemistry and Molecular Biology (SBBq)
Resumen:
CDC42 as an epigenetic regulator of ID4 in breast cancerDaniela Nasif, Sergio Laurito, María Roqué and María T. BranhamIHEM, National University of Cuyo, CONICET, Mendoza, Argentina.Introduction: Breast cancer can be classified as luminal A, luminal B, human epidermal growth factor receptor 2 and triple-negative (TN). Clinically, TN subtype has an aggressive nature, higher rates of relapse and shorter overall survival. Inhibitor of differentiation proteins 1, 2, 3 and 4 (ID1?4), are dominant negative regulators of the basic helix-loop helix family of transcription factors. In TN tumors, increased expression of ID4 proteins has been associated with reversion to an embryonic-like state, high rates of proliferation and migration. We have shown that ID4 promoter hypomethylation is associated with TN subtype. Also, that ID4 hypomethylation is associated with BRCAness phenotype and BRCA1 downregulation. Cdc42 is a plasma membrane-associated small GTPase, whose expression is dysregulated in several tumor types. Here we show that the overexpression of CDC42 reduced the aggressive phenotype of the MDA-MB-231 cells through the methylation of ID4 promoter and upregulation of BRCA1. Methods and Results: MDA-MB321 cell lines were transfected with a CDC42-GFP vector. ID4 methylation was measured by droplet digital, MS PCR and MS-MLPA assay. ID4 methylation increased after CDC42 transfection (p